CA3082945A1 - Liquid formulation comprising paeonol and apocynin - Google Patents

Liquid formulation comprising paeonol and apocynin Download PDF

Info

Publication number
CA3082945A1
CA3082945A1 CA3082945A CA3082945A CA3082945A1 CA 3082945 A1 CA3082945 A1 CA 3082945A1 CA 3082945 A CA3082945 A CA 3082945A CA 3082945 A CA3082945 A CA 3082945A CA 3082945 A1 CA3082945 A1 CA 3082945A1
Authority
CA
Canada
Prior art keywords
apocynin
paeonol
isomer
excipient
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3082945A
Other languages
English (en)
French (fr)
Inventor
Nicholas John Larkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akl Research & Development Ltd
Original Assignee
Akl Research & Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akl Research & Development Ltd filed Critical Akl Research & Development Ltd
Publication of CA3082945A1 publication Critical patent/CA3082945A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CA3082945A 2017-11-23 2018-11-22 Liquid formulation comprising paeonol and apocynin Pending CA3082945A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1719464.8 2017-11-23
GB1719464.8A GB2568698A (en) 2017-11-23 2017-11-23 Formulation
PCT/EP2018/082178 WO2019101842A1 (en) 2017-11-23 2018-11-22 Liquid formulation comprising paeonol and apocynin

Publications (1)

Publication Number Publication Date
CA3082945A1 true CA3082945A1 (en) 2019-05-31

Family

ID=60950758

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3082945A Pending CA3082945A1 (en) 2017-11-23 2018-11-22 Liquid formulation comprising paeonol and apocynin

Country Status (21)

Country Link
US (2) US11701325B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019005A1 (cg-RX-API-DMAC7.html)
JP (3) JP7314157B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250013306A (cg-RX-API-DMAC7.html)
CN (2) CN111372572B (cg-RX-API-DMAC7.html)
AU (2) AU2018371165B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082945A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124986T1 (cg-RX-API-DMAC7.html)
DK (1) DK3713546T3 (cg-RX-API-DMAC7.html)
ES (1) ES2906761T3 (cg-RX-API-DMAC7.html)
GB (1) GB2568698A (cg-RX-API-DMAC7.html)
HR (1) HRP20220303T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057595T2 (cg-RX-API-DMAC7.html)
LT (1) LT3713546T (cg-RX-API-DMAC7.html)
MX (2) MX393836B (cg-RX-API-DMAC7.html)
PL (1) PL3713546T3 (cg-RX-API-DMAC7.html)
PT (1) PT3713546T (cg-RX-API-DMAC7.html)
RS (1) RS62923B1 (cg-RX-API-DMAC7.html)
SI (1) SI3713546T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200101T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019101842A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2568698A (en) * 2017-11-23 2019-05-29 Akl Res & Development Ltd Formulation
GB202218160D0 (en) * 2022-12-02 2023-01-18 Akl Res & Development Ltd Formulation
CN119033608B (zh) * 2024-11-01 2025-03-25 深圳杉海创新技术有限公司 一种具有抑菌作用的低共熔溶剂、微脂囊及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920700613A (ko) * 1989-05-16 1992-08-10 지구르트 퓌터 약제제
CN100544708C (zh) * 2004-08-18 2009-09-30 上海佰加壹医药有限公司 一种丹皮酚软胶囊及其制备方法
GB2424833B (en) * 2005-04-08 2008-12-10 Nicholas John Larkins Anti-inflammatory formulation comprising apocyanin and paeonol
GB2463080A (en) * 2008-09-02 2010-03-03 Nicholas John Larkins Pharmaceutical preparation
GB201115757D0 (en) * 2011-09-12 2011-10-26 Akl Inflammatory Ltd Formulation for the treatment of benign prostate hyperplasia
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
GB2547241A (en) * 2016-02-11 2017-08-16 Akl Res & Dev Ltd Anti-inflammatory formulation
GB2568698A (en) * 2017-11-23 2019-05-29 Akl Res & Development Ltd Formulation

Also Published As

Publication number Publication date
NZ764238A (en) 2025-12-19
HRP20220303T1 (hr) 2022-05-13
CN116999417A (zh) 2023-11-07
CY1124986T1 (el) 2023-01-05
PT3713546T (pt) 2022-02-02
GB2568698A (en) 2019-05-29
MX2020005313A (es) 2020-08-17
GB201719464D0 (en) 2018-01-10
US20200297628A1 (en) 2020-09-24
LT3713546T (lt) 2022-03-10
JP2023104963A (ja) 2023-07-28
EP3713546B1 (en) 2021-12-08
KR20200090858A (ko) 2020-07-29
JP2025065531A (ja) 2025-04-17
CN111372572B (zh) 2023-08-29
AU2018371165B2 (en) 2024-02-29
ES2906761T3 (es) 2022-04-20
US20230330017A1 (en) 2023-10-19
CN111372572A (zh) 2020-07-03
MX2022008551A (es) 2022-08-10
JP2021504461A (ja) 2021-02-15
AU2024203514B2 (en) 2026-03-19
HUE057595T2 (hu) 2022-05-28
WO2019101842A1 (en) 2019-05-31
PL3713546T3 (pl) 2022-05-02
AU2024203514A1 (en) 2024-06-20
US11701325B2 (en) 2023-07-18
RS62923B1 (sr) 2022-03-31
SI3713546T1 (sl) 2022-04-29
SMT202200101T1 (it) 2022-03-21
EP3713546A1 (en) 2020-09-30
AU2018371165A1 (en) 2020-05-21
EP4019005A1 (en) 2022-06-29
KR102758107B1 (ko) 2025-01-20
DK3713546T3 (da) 2022-01-31
KR20250013306A (ko) 2025-01-31
JP7314157B2 (ja) 2023-07-25
MX393836B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
AU2024203514B2 (en) Liquid formulation comprising paeonol and apocynin
ES2245812T3 (es) Composicion para inhibir un aumento del nivel de azucar en sangre o disminuir el nivel de azucar en sangre.
ES2711935T3 (es) Conjugados de reína, método de preparación de los mismos y sus usos en la producción de medicamentos para tratar nefrosis diabética, adherencia intestinal y osteoartritis
ES2593858T3 (es) Método para preparar silibinina amorfa
WO2019209229A2 (en) Topical formulations comprising herbal extracts
US20150290268A1 (en) Formulations comprising herbal extracts
US11090346B2 (en) Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
Saini et al. Synergistic effect of piperine and its derivatives: a comprehensive review
CN102475698A (zh) 丹酚酸l在制备治疗肿瘤药物中的应用
US20260130964A1 (en) Pharmaceutical composition comprising high pay load ginger extract granules and process for preparation thereof
WO2006111085A1 (en) A method, formulation and use thereor with improved oral absorption of drugs or nutrients
CN113214207A (zh) 橙皮素与甜菜碱共晶物a及制备方法和其组合物与用途
JP5086805B2 (ja) 「抗ガン性野生チョウセンニンジンの精製エキス調整法及びそのガン融合製剤」
BR112020004364A2 (pt) método para preparar um extrato botânico de ácido abscísico
KR100485936B1 (ko) 진세노사이드 Rh2 및 Rg3 항암 조성물
CN118924714B (zh) 一种含mk-7药物组合物及其应用和制备方法
KR20250071993A (ko) 용출률과 안정성이 향상된 밀크시슬 함유 경구 투여용 제제 및 그 제조방법
CN120774875A (zh) 金合欢素与2,2’-联吡啶的共晶物及其用途
CN121401316A (zh) 一种神经疾病类药物组合物及其制备方法和用途
ACHARYA FORMULATION AND EVALUATION OF PHENYTOIN SODIUM SUSTAINED RELEASE MATRIX BASED TABLET
GB2547241A (en) Anti-inflammatory formulation
WO2016093680A1 (ru) Препарат на основе субстанции растительного происхождения, обладающий гепатопротекторным действием

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240704

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241119

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250106

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250106

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260330

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260330